Cambridge Healthtech Institute’s 2nd Annual

Targeting Tumor Myeloid Cells
( 肿瘤浸润骨髓细胞的标靶化 )

2018年9月27日~28日

Recently, our understanding of the Tumor Microenvironment (TME) has shed light onto the importance of tumor-infiltrating myeloid cells, such as tumor-associated neutrophils TANs, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and tumor-associated dendritic cells (TADCs), as critical contributors to the suppression of innate and adaptive immune responses. Importantly, these cells exist in various states within the TME, producing either immunosuppressive or immunostimulatory responses. Therapeutically targeting of tumor myeloid cells to eliminate or to convert them to their immunostimulatory state has emerged as a new and complementary strategy in the suite of cancer immunotherapy approaches. However, our understanding of tumor-resident myeloid cell phenotype and their possible divergent function in the tumor microenvironment is still not elaborated.

 

Cambridge Healthtech Institute’s 2nd Annual Targeting Tumor Myeloid Cells conference will bring together experts in the field to examine their phenotypic complexity and possible functions in connection with the tumor microenvironment. We will also discuss evidences for their contribution to cancer pathogenesis from new clinical studies along with regulation mechanisms of myeloid cells by tumors.

 

Who should attend: Executives, Medical Doctors, Directors, Managers, Researchers, and Scientists from pharma, biotechs, academia, government and healthcare organizations working in fields such as oncology, molecular biology, immunology, drug discovery, biologics, and cancer immunotherapy

 

Coverage will include, but is not limited to:                                        

  • Understanding the role of tumor-associated myeloid cells in the TME
  • Strategies for targeting tumor-associated neutrophils TANs, myeloid-derived suppressor cells (MDSCs), tumor-associated macrophages (TAMs), and tumor-associated dendritic cells (TADCs)
  • Novel agents targeting tumor-associated myeloid cells
  • New preclinical and clinical studies
  • Complexity of the tumor-resident myeloid cell phenotype and their divergent function in the TME
  • Regulation mechanisms of myeloid cells by tumors
  • Cancer cell stemness association
  • Combination immunotherapy development      

 

* 活动内容有可能不事先告知作更动及调整。

Choose your language
Chinese
Japanese
Korean
English





免费电子邮件通知服务